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A comparative analysis between sequential
boost and integrated boost intensity-
modulated radiation therapy with
concurrent chemotherapy for locally-
advanced head and neck cancer
Gregory Vlacich1,5*, Mark J. Stavas1, Praveen Pendyala2, Shaeu-Chiann Chen3, Yu Shyr3 and Anthony J. Cmelak1,4
Abstract
Background: Planning and delivery of IMRT for locally advanced head and neck cancer (LAHNC) can be performed
using sequential boost or simultaneous integrated boost (SIB). Whether these techniques differ in treatment-related
outcomes including survival and acute and late toxicities remain largely unexplored.
Methods: We performed a single institutional retrospective matched cohort analysis on patients with LAHNC
treated with definitive chemoradiotherapy to 69.3 Gy in 33 fractions. Treatment was delivered via sequential boost
(n = 68) or SIB (n = 141). Contours, plan evaluation, and toxicity assessment were performed by a single experienced
physician. Toxicities were graded weekly during treatment and at 3-month follow up intervals. Recurrence-free
survival, disease-free survival, and overall survival were estimated via Kaplan-Meier statistical method.
Results: At 4 years, the estimated overall survival was 69.3% in the sequential boost cohort and 76.8% in the SIB
cohort (p = 0.13). Disease-free survival was 63 and 69% respectively (p = 0.27). There were no significant differences
in local, regional or distant recurrence-free survival. There were no significant differences in weight loss (p = 0.291),
gastrostomy tube placement (p = 0.494), or duration of gastrostomy tube dependence (p = 0.465). Rates of acute
grade 3 or 4 dysphagia (82% vs 55%) and dermatitis (78% vs 58%) were significantly higher in the SIB group
(p < 0.001 and p = 0.012 respectively). Moreover, a greater percentage of the SIB cohort did not receive the
prescribed dose due to acute toxicity (7% versus 0, p = 0.028).
Conclusions: There were no differences in disease related outcomes between the two treatment delivery
approaches. A higher rate of grade 3 and 4 radiation dermatitis and dysphagia were observed in the SIB group,
however this did not translate into differences in late toxicity. Additional investigation is necessary to further
evaluate the acute toxicity differences.
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Background
Radiation therapy for locally advanced squamous cell
carcinoma of the head and neck (LAHNC) has changed
considerably over the past two decades with the advent
of intensity modulated radiation therapy (IMRT). While
the toxicity profile for patients with LAHNC has im-
proved, significant acute and late toxicities remain. In
the pre-IMRT era, definitive treatment consisted of con-
ventional radiation at a constant dose-per-fraction with
successive narrowing of fields to account for normal tis-
sue tolerances. With newer IMRT techniques, one can
differentially dose gross disease, high-risk subclinical,
and low-risk subclinical disease without changing the
overall treatment volume. This planning technique
gained popularity because of improved planning effi-
ciency (only a single inverse treatment plan is required),
and early studies suggesting improved dose distributions
[1, 2]. As a result, this method of IMRT, often referred
to as simultaneous integrated boost (SIB), became the
predominant mode of delivering radiation for LAHNC.
Studies have shown that dose-per-fraction to gross dis-
ease as high as 2.2 Gy/fraction with concurrent chemo-
therapy [3] and 2.4 Gy/fraction with radiation alone [4]
with integrated boost are safe and effective. Conversely,
a dose-per-fraction as low as 1.6 Gy/fraction shows
equivalent tumor control to the more conventional
2.0 Gy/fraction [5]. Despite this working range, there has
been variability among integrated boost regimens with
regard to toxicity and outcome profiles [6].
As inverse treatment planning techniques continue to
improve, a renewed interest in sequential boost planning
has developed. To date, few studies directly examine the
differences between sequential boost and SIB IMRT in
the treatment of LAHNC. Purely dosimetric studies on
limited patient numbers or patient surrogates have var-
ied regarding the advantage of one technique over the
other. Older studies suggested that SIB improved normal
tissue sparing and/or improved conformality [1, 7, 8],
while recent studies demonstrate reduced dose to nor-
mal structures in the neck, and improvement in con-
formality with sequential boost IMRT [9, 10]. Studies
comparing clinical outcomes and toxicities among pa-
tients treated with either technique are lacking. A recent
randomized study from Thailand explored toxicities and
outcomes in a small cohort of nasopharyngeal carcinoma
patients and showed no difference in acute toxicity rates
or early outcomes between the two IMRT techniques [11].
However, the absence of more common head and neck
cancer subtypes in this study and the low overall rate of
grade 3 or higher toxicity compared to historical controls
may limit the applicability of these results.
At our institution, a transition from SIB to sequential
boost IMRT for LAHNC was intentionally made for all
patients. This was based on clinical observations that
many SIB patients developed acute radiation toxicities
requiring treatment breaks or premature treatment com-
pletion and sequential boost was attempted to mitigate
these effects. In this study, we evaluate the toxicities,
survival, and recurrence rates associated with sequential
boost IMRT versus SIB in consecutive cohorts of pa-
tients using similar concurrent chemotherapy.
Methods
Design and patients
We performed a retrospective chart review of consecu-
tive patients who received definitive concurrent chemo-
radiotherapy with either SIB or sequential boost IMRT
for LAHNC between April 2003 and February 2012. Eligi-
bility included biopsy-proven AJCC Stage III-IVB squa-
mous cell carcinoma of the head and neck for which
curative surgical resection was not indicated or recom-
mended. Stage II patients were included if they received
comprehensive nodal irradiation with concurrent chemo-
therapy. Primary tumor sites included nasopharynx, para-
nasal sinus, oropharynx, oral cavity, hypopharynx, and
larynx. Patients with unknown primary were also eligible
if pharyngeal and nodal radiation was delivered. Patients
were at least 18 years old with an Eastern Cooperative
Oncology Group (ECOG) performance status of 0–2. Ex-
clusion criteria included prior oncologic resection, chemo-
therapy, or radiotherapy for their head and neck cancer, or
concurrent active malignancy. Patients with stage IVC dis-
ease at diagnosis were excluded except those with regional
metastases amenable to treatment with curative intent.
This study was approved by the Institutional Review
Board of Vanderbilt University.
Because there was an intentional and comprehensive
shift from SIB to sequential boost by the treating radi-
ation oncologist, the cohort of eligible patients treated
with either technique are not overlapping and include all
patients regardless of stage, subsite, or specific disease
characteristics (e.g. bulky or extensive lymphadenop-
athy). Eligible patients were treated with SIB from ap-
proximately 2003 to 2008 and with sequential boost
from approximately 2009 to 2012, thus accounting for
the relatively larger SIB cohort and the variable follow
up between groups.
Radiation treatment planning and dose-volume analysis
Radiation was delivered using IMRT. Patients underwent
CT-based simulation with immobilization using a cus-
tom thermoplastic mask (Aquaplast, Wycoff, NJ). Im-
aging studies and clinical exam with endoscopy were
utilized in tumor delineation. Based on these evalua-
tions, a gross tumor volume (GTV) was generated. Clin-
ical target volume (CTV)/planning target volume (PTV)
expansion of the primary GTV involved individualized
expansions based on location and specific at-risk sites of
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subclinical disease, but generally involved a composite
margin of 1.0–1.5 cm around the GTV. Lymph node
levels were contoured based on the Radiation Therapy
Oncology Group consensus guidelines and routinely in-
cluded bilateral level II–IV lymph nodes [12]. For in-
volved nodal levels, the entire level as defined above was
treated to the gross tumor prescription dose. If involved
at presentation, Level I and/or V lymph nodes were also
included and were covered prophylactically as clinically
indicated. For patients with unknown primary, compre-
hensive nodal and pharyngeal irradiation was performed.
Treatment volume definitions and expansions were con-
sistent between SIB and sequential boost groups.
Normal and avoidance structures were typically con-
toured based on their anatomic definitions. Skin was con-
toured as 3–5 mm from the surface. Treatment planning
was then performed using Eclipse treatment planning soft-
ware (Varian Medical Systems, Palo Alto, CA) and plans
evaluated using dose-volume histograms. Dose to ≥ 95% of
the target volume was required to be within ± 5% of the
prescribed dose. Dose to ≥ 95% of the prophylactically
treated nodal volume was required to be within + 8%
to −5% of the prescribed dose. The maximum dose to the
spinal cord and brain was required to be <4500 cGy and
the median dose to total parotid gland tissue was required
to be <2000 cGy. For non-laryngeal tumors, treatment
plans attempted to achieve a dose ≤ 2000 cGy to 50%
of the laryngeal volume and a maximal dose to the
pharyngeal constrictors <5000 cGy to minimize toxicity.
Dose and volume characteristics for organs at risk includ-
ing the larynx, base of tongue and esophagus were docu-
mented for each individual and compared.
Radiation dose and fractionation
For sequential boost radiation, the tumor and involved
and prophylactic nodal volumes all received 50.4 Gy at
2.1 Gy/fraction. Gross tumor and involved nodal volumes
then received an additional 18.9 Gy at 2.1 Gy/fraction for a
total dose of 69.3 Gy in 33 fractions. For SIB, tumor and
involved nodal volumes received 69.3 Gy in 2.1 Gy/fraction
as above, and prophylactic nodal levels received
1.7 Gy/fraction to 56.1 Gy in 33 fractions. Treatment was
delivered via a Varian Clinac 2100 or Varian Trilogy with
6 MV photons and 7 to 9 radiation fields using a step-
and-shoot method with sliding window technique. VMAT
was not utilized in either cohort. Treatment was given
once a day for 5 consecutive days each week. Treatment
plans were required to meet coverage thresholds and nor-
mal tissue constraints as described above. All IMRT treat-
ment plans underwent independent departmental review.
Chemotherapy
Induction chemotherapy was used at the discretion of
the treating medical oncologist, and it was typically
offered to patients with a bulky tumor, N3 disease, or
prominent level IV or V lymph nodes. In both cohorts,
induction chemotherapy consisted of weekly paclitaxel
60 mg/m2 and carboplatin area under the concentration-
time curve (AUC) 2 for a total of 9 weeks for most pa-
tients. Other regimens were rarely utilized as described in
Additional file 1: Table S1. All patients in the SIB cohort
and the vast majority in the sequential boost cohort
received concurrent weekly paclitaxel 30 mg/m2 and
carboplatin AUC 1 given with approximately 7 weeks
of radiation.
Assessment of complications
Toxicities were graded according to the current version
of the Common Terminology Criteria for Adverse Events
at the time of treatment (http://ctep.cancer.gov/protocol
Development/electronic_applications/ctc.htm). Acute ra-
diation toxicities were graded weekly in a prospective
manner by a single treating radiation oncologist, and a nu-
merical grade was recorded directly at the time of evalu-
ation. “Grade 0” was also utilized prospectively in any
category when there were no clinical findings or reported
symptoms. When no numerical grade was recorded and
insufficient data was available to assign a grade, no data
was recorded for that week. The highest-grade toxicity
achieved during the course of radiation was used for ana-
lysis. All patients were evaluable in the sequential boost
cohort. All patients in the SIB cohort were evaluated for
treatment outcome, but toxicity analysis was limited to
patients treated at Vanderbilt University Medical Center
(and not our satellite facilities) (n = 88). For each acute
toxicity, there was insufficient data to reliably assign any
grade during the entire course of treatment in a small
fraction of patients from each cohort. Subsequent analyses
were limited only to patients with available data, thus ac-
counting for the variable n values in Table 3.
Follow-up
Follow-up was performed as described previously [13].
Biopsy of suspicious lesions was performed to formally
establish treatment failure. Consensus option of a multi-
disciplinary tumor board was required to establish treat-
ment failure in the absence of biopsy.
Statistical methods
Data were analyzed using R version 3.1.0. Overall survival
(OS) was defined as the time from diagnosis to death from
any cause. Disease-free survival (DFS) was defined as the
time from diagnosis to any type of recurrence or death
from any cause. Local or regional recurrence was defined
as recurrence at the primary site or nodal sites respect-
ively. OS, DFS, local and regional recurrence-free survival,
and distant disease-free (or metastasis-free) survival were
estimated using the Kaplan-Meier statistical method.
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Differences between sequential and integrated boost co-
horts were evaluated using the Log-Rank test. Univariate
analysis with Log-Rank tests was used to identify signifi-
cant prognostic variables for DFS. Multivariate analysis
was performed using the Cox proportional hazards model.
For comparison of acute toxicity rates between cohorts,
the Wilcoxon rank sum test for continuous/ordinal vari-
ables was utilized and the Pearson chi-square test was
used to compare the incidence of “low” (grade 0–2) and
“high” (grade 3 and 4) grade toxicity between cohorts.
Dosimetric variables were compared using descriptive sta-
tistics and two tailed student t-test. p values <0.05 were
considered statistically significant.
Results
Patient and tumor characteristics
Patient and tumor characteristics are listed in Table 1.
Sixty-eight patients received concurrent chemoradiation
with sequential boost IMRT and 141 patients received
SIB between April 2003 and February 2012. The median
age at diagnosis was 60 (range, 30 to 75) in the sequen-
tial cohort and 57 (range, 37–88) in the SIB cohort.
Median follow up in the sequential boost cohort is
30.6 months (range, 6.1 to 54.7 months for surviving pa-
tients), whereas the SIB cohort, upon update from initial
analysis [13], had a median follow up of 57.8 months
(range, 2.4 to 97.1 months). There was a male predomin-
ance in both groups, and the majority of patients had
stage IVA disease and primary oropharyngeal cancer.
The sequential boost cohort had a larger percentage of
oropharyngeal tumors (and less nasopharynx and oral
cavity) and a higher proportion of patients with an
ECOG performance status of 2 (13% vs. 3%). Otherwise,
the cohorts were well matched.
Feasibility
Induction chemotherapy was administered to 78% of pa-
tients in the sequential boost and 68% of patients in the
SIB cohorts (p = 0.14). All patients received weekly
chemotherapy concurrent with IMRT, with all (100%) in
the SIB cohort and nearly all (95%) in the sequential
boost cohort receiving weekly carboplatin/paclitaxel. Alter-
native induction and concurrent chemotherapy regimens
are listed in Additional file 1: Table S1. Two sequential
boost patients (3%) required a >5 consecutive day break
from radiation treatment, similar to the 5% observed in the
SIB cohort [13]. A greater percentage of patients in the se-
quential boost cohort received 4 or less cycles of concur-
rent chemotherapy (24% vs. 4%, p < 0.001). Reasons for not
being able to complete 5 or more cycles were varied and
included hematologic toxicity, patient compliance, and/or
declining performance status in addition to delays from
radiation-related toxicity.
Dose and volume characteristics
Dose and volume characteristics for the larynx, base of
tongue, and esophagus are reported in Table 2. The aver-
age volume of structure contoured, mean dose, max
dose, and percent volume receiving 30 and 70 Gy were
analyzed. No differences in contoured volumes or dose
delivered to those volumes were considered to be statis-
tically significant between the two cohorts.
Toxicity
There were no treatment-related deaths in either cohort.
The percentage of patients requiring a modification to
their radiation treatment (i.e. a break or an incomplete
course) was comparable between the sequential boost and
SIB cohorts (44% vs 43%, p = 0.91). However, a greater
percentage of the SIB cohort did not receive the total pre-
scribed dose due to reported acute toxicity (7% versus 0%,
p = 0.028). There were no significant differences in the
Table 1 Patient and tumor characteristics
Sequential boost
cohort
Simultaneous integrated
boost cohort
Characteristic Number (%) N = 68 Number (%) N = 141
Sex
Male 56 (82) 122 (87)
Female 12 (18) 19 (13)
Age (Median) 60 (30–75) 57 (37–88)
Initial primary tumor site
Hypopharynx 2 (3) 6 (4)
Larynx 15 (23) 30 (21)
Nasopharynx 1 (1) 12 (9)
Oral Cavity 1 (1) 6 (4)
Oropharynx 48 (71) 81 (58)
Paranasal Sinus 0 (0) 2 (1)
Unknown primary 1 (1) 4 (3)
AJCC stage
Stage II 2 (3) 3 (2)
Stage III 15 (23) 37 (26)
Stage IVA 44 (64) 83 (59)
Stage IVB 5 (7) 18 (13)
Stage IVC 2 (3) 0
ECOG Performance Status
0 20 (30) 39 (28)
1 39 (57) 97 (69)
2 9 (13) 5 (3)
Smoking Status
Current 25 (37) 65 (46)
Former 23 (34) 48 (34)
Never 20 (29) 28 (20)
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rate of gastrostomy tube placement (62% in sequential
boost vs 67% in SIB) or in the rate of prolonged
(>12 month) gastrostomy tube dependence (9% vs 12%).
Rates of common acute radiation-associated toxicities
in the sequential and integrated boost cohorts are listed
in Table 3. When comparing rates of “low” (grade 0–2)
versus “high” (grade 3–4) grade acute toxicity, there
were higher rates of grade 3/4 toxicity in the SIB cohort,
with more grade 3/4 dermatitis (p = 0.012), dysphagia
(p < 0.001) and a trend towards increased mucositis
(p = 0.09). There were no differences in the rate of
high-grade xerostomia. When limiting the analysis to indi-
viduals who completed ≥ 5 cycles of concurrent chemo-
therapy, the increased rate of high-grade dysphagia in the
SIB cohort remained significant (p = 0.002), but the rate of
high-grade dermatitis was comparable (p = 0.13). Interest-
ingly, the increased rate of high-grade mucositis became
statistically significant in the SIB cohort (p = 0.039) (see
Additional file 1: Table S2).
Treatment outcome
The overall outcomes of treatment are shown in Table 4.
Median overall survival has not been reached for either
cohort. At 4 years, overall survival (OS) was 69.3% in
the sequential boost cohort and 76.8% in the SIB cohort
(p = 0.13) (Fig. 1) and disease free survival (DFS) was 63
and 69% respectively (p = 0.27) (Fig. 2). Though not sta-
tistically significant, the decreased OS and DFS in the se-
quential boost cohort at the early time points may be
due in part to the higher age and rates of death from
intercurrent disease in this cohort (16% vs 12%). Regard-
less, the survival curves begin to converge by 48 months.
There was no difference in the local-, regional-, or dis-
tant recurrence-free survival and the Kaplan-Meier
curves are superimposed at essentially all time-points
(Figs. 3, 4 and 5).
Though p16 status was only known for a small portion
of patients in the sequential boost cohort, survival for
the 9 patients that were confirmed to be p16-positive
was approximately 89% at 4 years and, as expected, im-
proved over the patients with negative p16 status or the
unselected patient average.
Discussion
The widespread use of IMRT for definitive treatment of
LAHNC has resulted in an overall move from sequential
boost to integrated boost radiation planning. This shift
was influenced by early dosimetric studies suggesting
improved dose distribution, initial ease of designing one
plan versus two or more, and the predominance of using
the SIB technique in Cooperative Group studies [14, 15].
At our institution, we made a conscious shift away from
Table 2 Comparative Dose-volume characteristics between
sequential boost and integrated boost plans
Base of Tongue Sequential boost SIB p value
Volume 13.2 cc 12.5 cc p = 0.13
Mean 60.2 Gy 65.2 Gy p = 0.63
Max 72.8 Gy 71.8 Gy P = 0.85
V30 92.2% 97.5% p = 0.58
V70 41.3% 47% p = 0.09
Larynx
Volume 25.79 cc 26.8 cc p = 0.08
Mean 49.4 Gy 43.8 Gy p = 0.06
Max 74.3 Gy 73.6 Gy p = 0.31
V30 72% 60% p = 0.06
V70 10.7% 19.5% p = 0.06
Esophagus
Volume 7.8 cc 6.9 cc p = 0.09
Mean 25.6 Gy 27.2 Gy p = 0.19
Max 54.0 Gy 49.2 Gy p = 0.08
V30 34.6% 37.5% p = 0.31
V70 0.3% 0% p = 0.08
Table 3 Analysis of acute toxicity in sequential and integrated
boost cohorts
Sequential boost Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Dermatitis (n = 64) 0% 2% 40% 56% 2%
Mucositis (n = 63) 3% 8% 19% 68% 2%
Xerostomia (n = 60) 12% 53% 33% 2% 0%
Dysphagia (n = 65) 3% 5% 37% 55% 0%
Weight loss (n = 64) −14.25 lbs. (−1.6– −32.8)
% Weight loss 8.1% (0.8–23.0)
Simultaneous
integrated boost
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Dermatitis (n = 76) 0% 7% 15% 71% 7%
Mucositis (n = 73) 1% 3% 14% 79% 3%
Xerostomia (n = 70) 0% 56% 44% 0% 0%
Dysphagia (n = 75) 0% 1% 17% 79% 3%
Weight loss (n = 88) −12.65 lbs. (+14.5– −33.0)
% Weight loss 7.4% (0–18.3)
Table 4 Overall performance of patients treated with sequential
boost and integrated boost at 4 years
4 year follow up Sequential boost Integrated boost
Overall survival 69.3% (56.5–79) 76.8% (68.6–83.1)
Disease Free Survival 63% (50.4–73.3) 69% (60.4–76.1)
Local recurrence-free survival 88.2% (76.7–94.2) 85.9% (78.2–91)
Regional recurrence-free survival 92.1% (82.1–96.7) 91.6% (84.8–95.4)
Distant disease-free survival 89.9% (78.8–95.4) 88.9% (82–93.3)
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SIB to sequential boost IMRT for LAHNC based on our
clinical observation that patients treated with SIB experi-
enced more severe acute skin and pharyngeal toxicity and
seemed less likely to complete treatment. Here, we sys-
tematically examined the outcomes and acute toxicities of
comparable cohorts of consecutive patients who received
definitive chemoIMRT for LAHNC either with SIB or se-
quential boost techniques. This is the first study compar-
ing IMRT techniques among relatively large cohorts that
include the more predominant head and neck subsites
and were consecutively treated using similar chemother-
apy and dose-volume constraints. Overall, we find that
these techniques appear equivalent with respect to treat-
ment outcomes though sequential boost IMRT is associ-
ated with some improvement in rates of acute toxicity.
Specifically, dysphagia was consistently improved in
the sequential boost cohort. Dermatitis and mucositis
rates were also improved, however statistical significance
was variable depending on the group or sub-group ana-
lyzed. For instance, among the entire sequential boost
cohort, rates of high-grade dermatitis were improved
and high-grade mucositis were statistically comparable
to SIB, while among only patients that completed most
of their concurrent chemotherapy, this was reversed.
The paradoxical effect with mucositis slightly improving
(70% vs 68% grade 3/4) and dermatitis worsening (58%
vs 66% grade 3/4) as more cycles of concurrent chemo-
therapy were completed in the sequential boost cohort
is, in part, the consequence of chemotherapy being held
for high-grade mucositis. Patients receiving less chemo-
therapy for this reason will of course have worse muco-
sitis which prompted the initial decision to hold
Fig. 1 Kaplan-Meier estimates of overall survival for integrated boost
(black) and sequential boost (red)
Fig. 2 Kaplan-Meier estimates of disease-free survival for integrated
boost (black) and sequential boost (red)
Fig. 3 Kaplan-Meier estimates of local recurrence-free survival for
integrated boost (black) and sequential boost (red)
Fig. 4 Kaplan-Meier estimates of regional recurrence-free survival for
integrated boost (black) and sequential boost (red)
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systemic therapy, but may also have improved dermatitis
as a consequence. Additionally, the severity of dermatitis
(more so than dysphagia and mucositis) can vary de-
pending on factors independent of treatment volumes
and disease, such as body habitus.
These differences in acute toxicity do not appear to be
the results of variable dose and dose-volume parameters
to key structures between SIB and sequential boost
treatments. Instead, we postulate that the observed im-
provement in dermatitis and dysphagia seen clinically
with sequential boost is due to decreasing radiation ex-
posure to the lower neck and pharyngeal constrictors
from 7 to 5 weeks. As studies have shown that 1.6 Gy/
fraction results in equivalent tumor control with 2.0 Gy/
fraction [5], early responding tissues with a similar α/β
ratio such as mucosa and dermis should conversely have
a comparable extent of damage from and recovery be-
tween fractions [16]. Therefore, doses within this range
of 1.6–2.0 Gy should not significantly alter the overall
effect on acute toxicity on a per-fraction basis. However,
with fewer total fractions to normal tissue with sequen-
tial boost IMRT, the result would be decreased severity
of acute toxicity.
The addition of concurrent chemotherapy to definitive
radiation for locally advanced head and neck cancer is well
known to increase toxicity compared to radiation alone
[17–19]. Concurrent chemotherapy regimens are variable,
but historically these have been cisplatin based or have
included 5-FU. In our cohort, radiation was given with
concurrent weekly carboplatin/paclitaxel and many also
received weekly induction chemotherapy with the same
agents. While cisplatin and carboplatin/paclitaxel have not
been directly compared in a randomized fashion, this
combination is often utilized as primary induction or
concurrent chemotherapy or for patients unable to
tolerate cisplatin, and our group and others have reported
comparable treatment outcomes and acceptable toxicities
[13, 20–22]. Furthermore, rates of high grade toxicity with
concurrent carboplatin/paclitaxel seen in our SIB cohort
are comparable with rates reported with cisplatin or 5-
FU-containing regimens [13, 15, 17, 19]. Nevertheless,
whether the differences seen in acute toxicity between SIB
and sequential boost in our study would apply to patients
receiving traditional cisplatin-based chemotherapy is not
entirely clear and would require further evaluation.
A majority of patients in both cohorts also received
induction chemotherapy prior to chemoradiation. Induc-
tion carboplatin/paclitaxel was typically offered to indi-
viduals with bulky tumors or lymphadenopathy and/or
lower cervical lymphadenopathy, and was previously
shown to be well-tolerated with 15% or less grade 3 and
0–1.5% grade 4 hematologic toxicity [13]. The potential
impact of induction chemotherapy on subsequent tox-
icity during chemoradiation is difficult to ascertain in
our study given the small fraction of patients who did
not receive induction. However, the PARADIGM trial
reported no difference in rates of mucositis, pain, xeros-
tomia, or feeding tube dependency between those who
received induction chemotherapy and those who did not
[23]. Additionally, a recent meta-analysis confirmed that
induction chemotherapy had no impact on rates of non-
hematologic toxicity during the chemoradiation portion
of therapy as compared to chemoradiation alone [24].
Furthermore, we found no significant difference in the
utilization of induction chemotherapy between our SIB
and sequential boost cohorts. This suggesting that in-
duction chemotherapy is unlikely to contribute signifi-
cantly to rates of acute toxicity reported in our study or
the difference observed between cohorts.
As with chemotherapy regimens, there is often some
degree of variability in radiation dose and fractionation
used for definitive treatment of LAHNC. In our cohort,
gross disease was treated to 69.3 Gy in 2.1 Gy per frac-
tion. This is slightly hypofractionated when compared to
the traditional 70 Gy in 2 Gy per fraction, however our
dose and fractionation is similar to that used for concur-
rent treatment in nasopharyngeal carcinoma cooperative
studies and results in comparable BED3 and BED10 to
70 Gy in 2 Gy fractions [15]. Additionally, dose to the
prophylactic volumes is within the standard range for both
the SIB and sequential boost groups. For these reasons,
we feel that our reported results are applicable to other
common LAHNC radiation doses and fractionations.
Most prior studies comparing SIB and sequential
boost IMRT for LAHNC examined the differences from
primarily a dosimetric standpoint. To our knowledge,
our study is the largest to date exploring the clinical
consequences of these distinct treatment approaches
and the first to examine this difference among the most
Fig. 5 Kaplan-Meier estimates of metastasis-free survival for integrated
boost (black) and sequential boost (red)
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common head and neck subtypes. Recently, Songthong
et al. reported on their phase II/III trial comparing SIB
and sequential boost IMRT in patients with nasopharyn-
geal carcinoma and found no significant difference in
short-term treatment outcomes or acute toxicities [11].
While the prospective nature of this study circumvents
some of the limitations of ours and appears to contradict
our findings with regard to toxicity, a number of factors
call into question the strength of their conclusions and
broader applicability. First, they utilized a different dose/
fractionation scheme to gross disease in the SIB and se-
quential boost arm (2.12 Gy versus 2.0 Gy per fraction).
Second, the study was limited to patients with nasopha-
ryngeal carcinoma, which is significantly less common
than oropharyngeal and laryngeal carcinoma. Third and
most importantly, Songthong et al. report very low rates
of grade ≥3 acute toxicity in either group when compared
to historical controls (2–15% vs approximately 70%) [11,
15, 17, 19]. Furthermore, the study was powered to detect
a generous 20% difference in acute toxicity rates yet did
not reach the number of enrolled patients to achieve that
(122 versus target of 218) [11]. With unusually low rates
of high grade toxicity at less than 20% and effectively be-
ing powered to detect greater than a 20% difference, the
lack of a significant difference may be due to the fact that
this study was underpowered. In contrast, we report on a
larger cohort with rates of grade ≥3 acute toxicity more in
keeping with historical controls and were able to see a sig-
nificant difference in various acute toxicities.
In general, SIB and sequential boost IMRT offer directly
competing advantages and disadvantages with regard to
radiobiology and treatment planning. Relative to SIB, se-
quential boost IMRT allows for consistent dose-per-
fraction between all treatment volumes and throughout
the course of treatment. This addresses the theoretical
concern of under-dosing target volumes with 1.6–1.7 Gy
fractions, particularly in the latter weeks of treatment
when accelerated repopulation of tumor clonogens is
prevalent [25, 26]. Additionally, sequential plans can bet-
ter account for changes in body habitus (weight loss),
edema, and tumor shrinkage when a new CT is obtained
for boost planning. On the other hand, sequential boost
IMRT is more time consuming and involves the summa-
tion of 2 or more treatment plans, which can theoretically
result in more potential uncertainty in true dose distribu-
tion (particularly if based on separate CT simulations).
Centers with high volume and/or limited or inexperienced
staff find this more challenging compared to a single SIB
plan. Continuous improvements in treatment algorithms
and decreased time required for planning have improved
the overall throughput for sequential boost IMRT, though
these relative challenges still remain. Nevertheless, our
data suggest that despite their differences, these two tech-
niques are comparable with regard to treatment outcome.
As a retrospective analysis on two cohorts of patients
treated at distinct periods of time, this study is limited by
the lack of a prospective comparison of the two methods
of treatment planning. These differences are partly miti-
gated by the use of consecutive patients, similar chemo-
therapy regimens, similar dose-volume constraints for
IMRT, and prospective grading of toxicity by a single,
experienced radiation oncologist at the time of treatment.
The latter greatly minimizes the potential for intra- and
inter-observer variability in these more subjective values.
Furthermore, while the SIB and sequential boost patients
were treated during non-overlapping intervals of time be-
tween 2003 and 2012 with the SIB group treated earlier,
any differences in treatment planning, evaluation, and
delivery were minimized over that span of time due to a
number of factors. Specifically, contouring practices, treat-
ment machines, dose calculation algorithms, and treat-
ment planning software were consistent during this time.
Still, there may be less quantifiable changes between these
time periods that cannot be adequately accounted for.
Additionally, changes in acute toxicity were not associated
with gastrostomy placement or duration, weight loss, or
changes in late toxicity in our cohort. Therefore, all these
potential differences will need to be accounted for or
confirmed in a formalized, prospective manner.
Conclusions
Concurrent chemoradiation with sequential boost IMRT
for LAHNC is well-tolerated and results in treatment out-
comes comparable to simultaneous integrated boost. Our
institutional experience also suggests that sequential boost
reduces high-grade acute toxicity, and these data warrant
further evaluation in a prospective study. In this setting of
a potential reduction in acute toxicity, sequential boost
IMRT is especially appealing as an alternative to SIB as
image-guidance usage increases, particularly on-board
cone beam CT. This could potentially reduce toxicity even
further through real-time, clinically-guided modification
of target volumes. Coupling image-guided assessment of
tumor response with sequential field size reductions may
allow for truly adaptive radiotherapy in a way not possible
or practical with simultaneous integrated boost.
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